Frank Armstrong

Biography

Dr Armstrong has served as a member of the Board of Directors since November 2012 and as Non-Executive Chairman since June 2013. Prior to this, Dr Armstrong led Medical Science and Innovation at Merck Serono, the biopharmaceutical division of Merck KGaA, from 2010 to 2011. Dr Armstrong was also Head of Worldwide Product Development at Bayer AG from 1998 to 2001 and held various positions at ICI plc and Zeneca plc, now AstraZeneca plc, from 1985 to 1998. Dr Armstrong has served as the Chief Executive Officer at five biotechnology companies, including Fulcrum Pharma, CuraGen, which was acquired by Celldex Therapeutics Inc, Bioaccelerate, Provensis and Phoqus. Dr Armstrong is the Non-Executive Chairman of the Boards of Directors of Faron Pharmaceuticals Oy and Caldan Therapeutics Ltd. He is a Non-Executive Director on the Boards of Juniper Pharmaceuticals Inc, which is listed on NASDAQ and Mereo Biopharma Group plc. He is also a Member of the Strategic Advisory Board of HealthCare Royalty Partners. Dr Armstrong received an honours degree in Biochemistry and an MBChB in Medicine from the University of Edinburgh in Scotland. Dr Armstrong is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow of the Faculty of Pharmaceutical Physicians.

Research Interest

biotechnology